<DOC>
	<DOCNO>NCT00927784</DOCNO>
	<brief_summary>Left ventricular assist device ( LVADs ) one treatment option people congestive heart failure . This study evaluate safety inject mesenchymal precursor cell ( MPCs ) heart LVAD implantation surgery examine inject MPCs heart effective improve heart function .</brief_summary>
	<brief_title>Effect Intramyocardial Injection Mesenchymal Precursor Cells Heart Function People Receiving LVAD</brief_title>
	<detailed_description>Congestive heart failure major health problem recent estimate indicate end-stage heart failure 2-year mortality rate 70-80 % affect 60,000 people United States year . For patient , treatment option extremely limited . Less 3,000 heart transplant available year severely limit supply donor heart . Implantable LVADs , routinely used support heart transplantation patient decompensate await donor heart , approve Food Drug Administration ( FDA ) 2002 long-term support heart transplantation option . Few patient , however , achieve sufficient recovery warrant LVAD explantation must still contend ventricular dysfunction . MPCs normally present human bone marrow show increase development blood vessel new heart muscle cell . The purpose study determine safety inject MPCs heart LVAD implantation surgery . In addition , study examine whether inject MPCs heart effective improve heart function . This study enroll people wait list receive donor heart undergo LVAD implantation surgery . Before surgery , participant randomly assign one two group . One group participants MPCs injected heart LVAD surgery group participant control solution ( placebo ) inject heart surgery . A portion heart muscle remove surgery analyze . Participants monitor study researcher blood sample collect 12 hour LVAD surgery 1 , 7 , 21 , 60 , 90 day surgery . After , medical history review , physical examination , blood collection occur every 60 day heart transplant occur 12 month LVAD implantation , whichever come first . Heart function testing , include echocardiogram , neuronal function test , 6-minute walk test , occur 60 90 day LVAD implantation , every 2 month thereafter heart transplant occur 12 month LVAD implantation , whichever come first .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Signed informed consent , release medical information , Health Insurance Portability Accountability Act ( HIPAA ) document Age 18 year old If participant partner childbearing potential , must willing use adequate contraception ( hormonal barrier method abstinence ) time screen period least 16 week LVAD implantation Female participant childbearing potential must negative serum pregnancy test screening Admitted clinical center time study entry Listed United Network Organ Sharing ( UNOS ) heart transplantation Clinical indication accept candidate implantation FDA approve LVAD bridge transplantation Cardiothoracic surgery within 30 day study entry Heart attack within 30 day study entry Prior heart transplantation , leave ventricular ( LV ) reduction surgery , cardiomyoplasty Acute reversible cause heart failure ( e.g. , myocarditis , profound hypothyroidism ) Anticipated requirement biventricular mechanical support Stroke within 30 day study entry Received investigational intervention within 30 day study entry Platelet count le 100,000/uL within 24 hour study entry Active systemic infection within 48 hour study entry Presence great 10 % antihuman leukocyte antigen ( HLA ) antibody titer know specificity MPC donor HLA antigens Known hypersensitivity dimethyl sulfoxide ( DMSO ) , murine , and/or bovine product History cancer prior screen ( exclude basal cell carcinoma ) Acute chronic infectious disease , include limited human immunodeficiency virus ( HIV ) Treatment and/or incompleted followup treatment investigational therapy within 6 month study entry Active participation research therapy cardiovascular repair/regeneration Prior recipient stem precursor cell therapy cardiac repair Pregnant breastfeeding time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Mesenchymal Precursor Cells</keyword>
	<keyword>Left Ventricular Assist Device</keyword>
	<keyword>LVAD</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Stem Cells</keyword>
</DOC>